Mylan (NASDAQ: MYL), a United States-based global generic and specialty pharmaceuticals company, has signed a contract with the Medicines Patent Pool, it was reported yesterday.

The agreement has been signed to expand access to chronic hepatitis C medicines in developing countries. It licenses Mylan to produce and market a generic version of Bristol-Myers Squibb's DAKLINZA (daclatasvir) Tablets, 30 mg and 60 mg, for distribution in 112 low and middle income countries.

Daclatasvir Tablets, 30 mg and 60 mg, are indicated for use with sofosbuvir, with or without ribavirin intended for the treatment of patients with chronic hepatitis C virus genotype 1 or genotype 3 infection in the United States, and genotype 1, 3 and 4 in Europe. The license allows Mylan to produce fixed-dose combinations that offer the potential to treat all of the six major genotypes of HCV. Earlier this year, the World Health Organization added several new hepatitis C treatments, including daclatasvir, to its essential medicines list, highlighting the urgent need to promote equitable access to innovative medicines.